Takaki Manabu, Ujike Hiroshi
Department of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama City, Japan.
Clin Neuropharmacol. 2014 Jul-Aug;37(4):123-4. doi: 10.1097/WNF.0000000000000035.
Delayed sleep phase syndrome (DSPS) comprises a persistent or recurrent pattern of sleep disturbances, sleep disruption that leads to insomnia and/or excessive daytime sleepiness, and impaired functioning in social, occupational, or other spheres. Aripiprazole (APZ), a second-generation antipsychotic, manifests a novel mechanism of action by serving as a partial agonist of both D2 and serotonergic 5-HT1A receptors and antagonist of 5-HT2A receptors. We have used APZ to treat DSPS. One reason it was effective may be that the insomnia induced by daytime APZ was effective in treating the patient's daytime sleepiness. Another reason may be APZ increases histamine release which controls sleep-wake cycles. Thus, APZ may be therapeutic for DSPS.
延迟睡眠相位综合征（DSPS）包括持续或反复出现的睡眠障碍模式、导致失眠和/或日间过度嗜睡的睡眠中断，以及社交、职业或其他领域功能受损。阿立哌唑（APZ）是一种第二代抗精神病药物，通过作为D2和5-羟色胺能5-HT1A受体的部分激动剂以及5-HT2A受体的拮抗剂，表现出一种新的作用机制。我们使用APZ治疗DSPS。其有效的一个原因可能是日间使用APZ引起的失眠对治疗患者的日间嗜睡有效。另一个原因可能是APZ增加了控制睡眠-觉醒周期的组胺释放。因此，APZ可能对DSPS具有治疗作用。
